Novo Nordisk invests $100m in China expansion ahead of 2015 target
This article was originally published in Scrip
Novo Nordisk has invested $100 million to expand its R&D centre in Beijing, increasing the number of R&D employees from 130 to 200 with space available for future growth.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.